1 135 136 137 138 139 143
Number of results: 2842
Date Compound Product name Company Disease Action mechanism Type of Information
2012-03-02 peginesatide peginesatide Takeda Pharmaceutical (Japan) symptomatic anemia associated with chronic kidney disease (CKD) in adult patients on dialysis Peginesatide is a synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an…
2012-03-02 desmoteplase desmoteplase Lundbeck (Denmark)

acute ischaemic stroke


2012-03-02 EV-035 EV-035 Evolva (Switzerland) EV-035 is a bacterial type II topoisomerase inhibitor, belonging to the chemical class of 2-pyridones. EV-035 shows potent broad-spectrum activity,…
2012-02-29 GLPG0778 and its back-up compound GLPG0555 GLPG0778/GSK2586184 and its back-up compound GLPG0555 The compounds are small molecule kinase inhibitors.
2012-02-29 colistimethate sodium Colobreathe® dry powder Forest Laboratories (USA) treatment of cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P.
2012-02-23 ulipristal acetate Esmya® Preglem (Switzerland) member of the Richter Group (Hungary)

pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age

The active substance of Esmya® is ulipristal acetate, a selective progesterone receptor modulator, characterised by a tissue-specific partial progesterone antagonist… Granting of a Market Authorisation in the EU
2012-02-21 vandenatib Caprelsa® AstraZeneca (UK)

medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease

kinase inhibitor/tyrosine kinase inhibitor. This tyrosine kinase inhibitor is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and… Granting of a Market Authorisation in the EU
2012-02-20 vemurafenib Zelboraf® Roche (Switzerland) BRAF V600 mutation-positive metastatic melanoma kinase inhibitor. Vemurafenib is a BRAF-inhibitor and it is designed to selectively target and inhibit a mutated form of the… Granting of a Market Authorisation in the EU
2012-02-17 letermovir AIC246 Aicuris (Germany) prevention of HCMV (human cytomegalovirus) disease Letermovir (AIC246) is an innovative, highly active and specific inhibitor of HCMV. It stems from a novel chemical class (quinazolines)…
2012-02-17 granisetron Sancuso® transdermal patch ProStrakan (UK) prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult.
Granisetron is a highly selective antagonist of 5-hydroxytryptamine (5HT3 receptors). Pharmacological studies have demonstrated that granisetron is effective against nausea…
2012-02-16 Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine Menveo® Novartis (Switzerland) prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y vaccine
2012-02-08 NRP-1 small molecule antagonists NRP-1 small molecule antagonists Ark Therapeutics (UK) cancers Ark has developed the first drug-like small molecule antagonists of VEGF binding to NRP-1 which, in pre-clinical in vivo studies,…
2012-02-08 pertuzumab Perjeta® Genentech, a member of the Roche Group (USA - Switzerland)
  • use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease
monoclonal antibody. Pertuzumab is a humanized monoclonal antibody. It has been designed specifically to prevent the HER2 receptor from pairing… Granting of a Market Authorisation in the EU
2012-02-03 asparaginase Erwinia chrysanthemi Erwinaze® EUSA Pharma (USA) now Jazz Pharmaceuticals (USA)

treatment of patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegaspargase chemotherapy drugs used to treat ALL.

Asparagine is essential for cell growth. Neoplastic cells associated with ALL are lacking asparagine synthetase activity and rely on asparagine… Granting of a Market Authorisation in the US
2012-02-02 talactoferrin talactoferrin Agennix (Germany)

malignant neoplasms and other hyperproliferative diseases


Talactoferrin is an oral biologic therapy with immunomodulatory and antibacterial properties, which is being studied for the treatment of cancer…
2012-01-30 axitinib Inlyta® Pfizer (USA - NY)

advanced renal cell carcinoma

tyrosine kinase inhibitor/VEGFR inhibitor. Axitinib is an oral and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and… Granting of a Market Authorisation in the EU
2012-01-28 glucarpidase injection Voraxaze® BTG International (UK) treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Voraxaze® works by breaking down methotrexate into its inactive metabolites which are then eliminated from the body by routes other…
2012-01-27 interferon beta-1a Rebif® Merck KGaA (Germany) early signs of multiple sclerosis
2012-01-25 AFC-5128 AFC-5128 Affectis Pharmaceuticals (Germany) neuropathic pain
multiple sclerosis
AFC-5128  is a P2X7 antagonist
2012-01-23 MOR202 (anti CD38 antibody) MOR202 Morphosys (Germany) monoclonal antibody. MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma… Granting of a patent